september 2024

EADV24: Semaglutide Shows Promising Outcomes for Obese Patients with Hidradenitis Suppurativa

A study presented Wednesday, 25 September 2024, at the EADV Congress 2024 in Amsterdam highlights the significant potential of semaglutide in treating hidradenitis suppurativa (HS) in obese patients.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Få adgang
Hvis du allerede har en profil: Log ind

Relateret indhold

LBA: Lebrikizumab Provides Long-Term Efficacy and Safety in Atopic Dermatitis with a Well-Tolerated Safety Profile

september 2024 / Jan Andreasen

EADV24 Atopisk dermatitis

No Significant Changes in Incidence or Survival Rates of Acral Melanoma in Sweden

september 2024 / Teo Helkkula

EADV24 Melanom 04:45

Conversation Cards for Patients with Atopic Dermatitis

september 2024 / Anna Sophie Belling Krontoft

EADV24 Atopisk dermatitis 2:56

Exciting Data on Atopic Dermatitis from EADV 2024

september 2024 / April Armstrong

EADV24 Atopisk dermatitis 04:14

Key Findings on Deucravacitinib – A New Oral Treatment for Psoriasis

september 2024 / Melinda J. Gooderham

EADV24 Psoriasis 02:51

EADV24: New Insights Into Chronic Wound Healing – A Significant Step Forward to Changed Clinical Practice

september 2024 / Jan Andreasen

EADV24 Sårbehandling

Nyt om behandling af håndeksem

september 2024 / Claus Otto Carl Zachariae

EADV24 Eksem 02:34

A Multidisciplinary Approach to Chronic Leg Ulcers is Important so that Rarer Causes Go Undiagnosed

september 2024 / Marcela Nowak

EADV24 7:09

EADV24: New Research Confirms Link Between Stress and Psoriasis Relapse

september 2024 / Sofie Pohl

EADV24 Psoriasis

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen